Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2152 • 2012 ACR/ARHP Annual Meeting
Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-α Production
Jun Li¹, Hui-Chen Hsu², PingAr Yang¹, Qi Wu¹, David M. Spalding³, W. Winn Chatham⁴, Robert P. Kimberly⁵, S. Louis Bridges Jr.⁶ and John D. Mountz⁷, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Clinical Immunology & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁷Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL
Background/Purpose: Fucosylation, catalyzed by fucosyltransferases (Futs), is an important glycosylation process involved in inflammation, cell death, and differentiation. We have observed an extremely high positive correlation…
Abstract Number: 1584 • 2012 ACR/ARHP Annual Meeting
Validity of the Nurses Health Study II Physical Activity Questionnaire (NHSPAQ) in Estimating Physical Activity in Adults with Rheumatoid Arthritis (RA)
Maura D. Iversen¹, Thomas Quinn² and Michelle A. Frits³, ¹Department of Physical Therapy, Movement & Rehabilitation Sciences, Northeastern University, Boston, MA, ²Biology, Northeastern University, Boston, MA, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: An accurate assessment of physical activity (PA) is critical to manage rheumatoid arthritis (RA). Accelerometry is an objective measure of PA but is not…
Abstract Number: 652 • 2012 ACR/ARHP Annual Meeting
Serum Rituximab Levels and Efficiency of B-Cell Depletion: Differences Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Venkat Reddy¹, Sara Croca², Delia Gerona³, Inmaculada De La Torre Ortega³, David A. Isenberg⁴, Maria Leandro² and Geraldine Cambridge⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁴Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in rituximab-induced B-cell depletion (BCD) occurs in a significant number of patients with Systemic Lupus Erythematosus (SLE) and to a lesser extent in…
Abstract Number: 352 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis
Charlotte Hua¹, Thomas Barnetche², Bernard Combe³ and Jacques Morel⁴, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact…
Abstract Number: 2665 • 2012 ACR/ARHP Annual Meeting
Metabolic Reprogramming of Autoimmune T Cells in Rheumatoid Arthritis
Zhen Yang¹, Hiroshi Fujii², Shalini Mohan¹, Jorg J. Goronzy¹ and Cornelia M. Weyand³, ¹Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ³Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In RA, autoimmunity precedes clinical symptoms by a decade and persists unabated even when downstream inflammation is well controlled; exposing lymphocytes to chronic stimulation…
Abstract Number: 2129 • 2012 ACR/ARHP Annual Meeting
Dickkopf-1 Is Increased in Rheumatoid Arthritis of Recent Onset and Might Be a New Biomarker of Structural Progression. Data From the Espoir Cohort
Raphaèle Seror¹, Stephan Pavy², Thierry Schaeverbeke³, Alain Saraux⁴, Xavier Mariette⁵ and Corinne Miceli-Richard¹, ¹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²Hopital Bicetre, Paris, France, ³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁴Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ⁵Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Dickkopf-1 (DKK-1) is an inhibitory protein of the Wnt signalling pathway that could be involved in subchondral bone erosions occurring in rheumatoid arthritis (RA).…
Abstract Number: 1338 • 2012 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation
M.M. Herenius¹, A.S.F. Oliveira¹, C.A. Wijbrandts¹, D. Gerlag¹, Paul P. Tak² and Maria C. Lebre³, ¹Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Chemerin is a specific chemoattractant for macrophages and dendritic cells (DC). In addition, it can rapidly stimulate macrophage adhesion to extracellular matrix proteins and…
Abstract Number: 490 • 2012 ACR/ARHP Annual Meeting
12- and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Douglas E. Schlichting², Kimberly L. Sterling³, Edward Keystone⁴, Peter Taylor⁵, Mark C. Genovese⁶, Louise Johnson⁷, Juan C. Rizo Rodriguez⁸, Chin H. Lee² and Carol L. Gaich³, ¹Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada, ⁵Kennedy Institute of Rheumatology, London, United Kingdom, ⁶Division of Rheumatology, Stanford University, Palo Alto, CA, ⁷PharmaNet/i3, Eden Prairie, MN, ⁸Clinical Investigation, Centro de Alta Especialidad en Reumatología e Investigación del Potosí, San Luis Potosi, San Luis Potosi, Mexico
Background/Purpose: Baricitinib (formerly, LY3009104/INCB028050) is a novel, oral inhibitor of the JAK1 and JAK2 in the JAK-STAT pathway known to be of importance in the…
Abstract Number: 345 • 2012 ACR/ARHP Annual Meeting
Predictive Software-Based Mathematical Modeling: A Novel Approach to Development of Oral Therapies for Rheumatoid Arthritis – Validation in a Murine Collagen Induced Arthritis Model
Gurkirpal Singh¹, Robinson Vidva², Prashant Nair², Saumya Radhakrishnan², Pradeep Fernandes², Taher Abbasi², Canio Refino³, Jay Dela Cruz³ and Shireen Vali², ¹Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA, ²CellWorks Group, Saratoga, CA, ³InTouch Bio, Alameda, CA
Background/Purpose: Rheumatoid Arthritis (RA) involves complex interactions of multiple cell systems, cytokines and mediators, and interlinked signaling. While molecularly-targeted therapies manipulate specific interactions, it is…
Abstract Number: 2101 • 2012 ACR/ARHP Annual Meeting
How Much Can Patient Reported Outcomes Improve Among Rheumatoid Arthritis Patients Who Have a Clinical Response to Biologic Therapy but Have Not Attained Low Disease Activity?
Jeffrey R. Curtis¹, Ying Shan, Jie Zhang¹, Jeffrey D. Greenberg³ and George W. Reed⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²New York Hospital for Joint Disease, New York, NY, ³University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Current treat-to-target (T2T) recommendations suggest that rheumatoid arthritis (RA) patients should strive for remission or low disease activity (LDA) as a goal. Treatment changes…
Abstract Number: 1326 • 2012 ACR/ARHP Annual Meeting
Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons
Lillian J. Barra¹, Andrew Ha², Louise Sun³, Catarina Fonseca⁴ and Janet E. Pope⁵, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²The University of Toronto, Toronto, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Universidade de Lisboa, Lisbon, Portugal, ⁵Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy…
Abstract Number: 494 • 2012 ACR/ARHP Annual Meeting
Are There Gender Specific Differences in Patient Characteristics At Initiation of Biologic Treatment in Rheumatoid Arthritis?
William Bensen¹, Denis Choquette², Isabelle Fortin³, Alice V. Klinkhoff⁴, Susan M. Otawa⁵ and Hayssam Khalil⁶, ¹St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴The Mary Pack Arthritis Ctr, Vancouver, BC, Canada, ⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁶Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The prevalence of rheumatoid arthritis (RA) is 2-4 times higher in women compared to men depending on age. Furthermore, in women RA incidence increases…
Abstract Number: 195 • 2012 ACR/ARHP Annual Meeting
Inflammatory Arthritis in Patients with Myelodysplastic Syndrome: French Multicenter Retrospective Study
Arsene Mekinian¹, Olivier Decaux², Geraldine Falgarone³, Thorsten Braun Sr.⁴, Eric Toussirot⁵, Loic Raffray⁶, Bruno Gombert⁷, Bruno de Wazieres⁸, Anne Laure Buchdaul⁹, Jean-Marc Ziza¹⁰, David Launay¹¹, Guillaume Denis¹², Serge Madaule¹³, Pierre Fenaux¹⁴ and Olivier Fain¹⁵, ¹Internal Medicine, Jean Verdier Hospital, Bondy, FL, France, ²Department of Internal Medicine, Rennes University Hospital, Rennes, France, ³Rheumatology, Hopital avicenne, Paris, France, ⁴Hematology, Avicenne hospital, Bobigny, France, ⁵Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ⁶Internal Medicine, CHU de Bordeaux, Bordeaux, France, ⁷Internal Medicine, La Rochelle hospital, La Rochelle, France, ⁸Internal Medecine, CHU de Nimes, Nimes, France, ⁹Internal Medicine, Douai hospital, Douai, France, ¹⁰Rheumatology, Croix Saint Simon Hospital, Paris, France, ¹¹Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹²Internal Medicine, Rochefoucault hospital, Rochefoucault, France, ¹³Rheuamtology, Albi hospital, Albi, France, ¹⁴Hematology, Avicenne Hospital, France, ¹⁵Internal Medicine, Jean Verdier Hospital, Bondy, France
Inflammatory arthritis in patients with myelodysplastic syndrome: French multicenter retrospective study.For the Société Nationale Française de Médecine Interne (SNFMI), the CRI (Club Rhumatismes Inflammation) and…
Abstract Number: 2107 • 2012 ACR/ARHP Annual Meeting
Assessing Subclinical Synovitis in Rheumatoid Arthritis: Arthrosonographic Findings in Patients with Good Response to Therapy
Matthias Witt¹, Felix Mueller², Axel Nigg², Christiane Reindl³, Hendrik Schulze-Koops² and Mathias Grunke², ¹Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Division of Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ³Division for Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany
Background/Purpose: Treat-to-target is a key principle in rheumatoid arthritis. Composite scores such as the DAS-28 help to monitor disease activity and response to therapy. However,…
Abstract Number: 1310 • 2012 ACR/ARHP Annual Meeting
Analysis of Anti-JC Polyomavirus T-Cell Immune Response with JC-Feron in Patients with Rheumatoid Arthritis Treated with Rituximab or Anti-TNF
Raphaèle Seror¹, Houria Chavez², anne-Aurélie Mazet³, Jeremie Sellam⁴, Bruno Fautrel⁵, Maxime Dougados⁶, Yassine Taoufik² and Xavier Mariette⁷, ¹Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ²Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, ³Virology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁴Rheumatology, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 75012, France, ⁵Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁶Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Some cases of progressive multifocal leukoencephalopathy (PML) have been described in patients with autoimmune diseases with profound immunosuppression, due to replication of JC polyomavirus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].